Sales of summer heat prevention drugs in large pharmacies increased significantly
Release time:
2022-08-24
News from our newspaper # The high temperature continued after February, which is the peak season for sales of heatstroke prevention and cooling drugs. Peak pharmacies seized the opportunity to actively expand group buying customers, with significant year-on-year growth in the number of customers and sales.
Since the new crown epidemic, store epidemic prevention requirements are strict, customers need to enter the store multiple steps, coupled with four categories of drug sales restrictions, retail pharmacy business has generally been affected. In the face of difficulties, Jianfeng Pharmacy has actively explored its ideas and looked for sales growth points. From July , it has carefully selected the categories of heatstroke prevention drugs and has planned stock to ensure sufficient supply of goods and drugs in summer, so as to purchase a variety of varieties and varieties. Each category is equipped with multiple manufacturers, high, medium and low prices, for different customers to choose according to their respective situations.
The summer weather this year was sultry. There was no continuous precipitation after entering the plum. The high temperature weather started early and lasted for a long time. The heatstroke prevention and cooling drugs were popular. Jianfeng Pharmacy maintains old customers and develops new customers. Actively contact customers with more outdoor operations such as logistics and construction and more high-temperature workers; Actively participate in the bidding for heatstroke prevention drugs and group buying products. Fang Yanfei, manager of Shuangxi Store, who is responsible for contacting customers, said that the sales are mainly small group purchases, with a relatively small total amount and a large number of customers. According to the working characteristics and budget of different customers, drug combinations with different prices have been prepared. Each drug has been compared with other merchants in advance to set a reasonable price and improve the success rate of group purchases. In summer, many pharmacies are competing for the group purchase business of heatstroke prevention drugs. Some customers communicated four or five times and discussed it for a long time. Through hard work, the number of customers of group purchase of heatstroke prevention drugs increased from11 in the same period last year to 20 enterprises and institutions, with sales increasing by 209% year on year.
After the group purchase is negotiated, the business department will quickly transfer the goods according to the customer's demand to ensure timely supply. Among the heatstroke prevention drugs, liquid drugs such as Huoxiang Zhengqi water account for a large proportion. When delivery, customers have to be moved into warehouses, and some have to be transported upstairs. Most pharmacies are female employees, but everyone still overcomes difficulties and provides customers with the best quality. service. In addition to the group buying business, each store also has a variety of products for customers to buy in the store.Summer heatstroke prevention drug group purchase has increased, but it belongs to seasonal sales, the total amount is relatively small, and the gross profit of some drugs is low. In the future, the peak pharmacy will adjust its sales focus in due course, strengthen the sales of tonic drugs in autumn and winter, and intensify its efforts to build a famous doctor of traditional Chinese medicine. Continuously improve the product structure, implement
"one product with multiple regulations" in each store, and implement multi-manufacturer, multi-grade and multi-specification matching to promote sales of products with large sales volume; We should dig new growth points from multiple angles and seek ways to "break the game. (Reporter
Chen Shengmu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page